Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Ainos acquired exclusive, permanent licenses for 10 patents and patent applications from its affiliate and development partner, Taiwan Carbon Nano Technology (TCNT), for certain gas sensor and medical device technologies.</li><li>TCNT is also currently the sole manufacturer of Ainos’ POCTs. The patent coverage includes the US, Germany, China, Japan, and Taiwan.</li><li>The licensed IP will further enhance the company’s AI Nose and POCT platform, as the lead POCT product Ainos Flora progresses in clinical trial, and design completion for next-gen Ainos Flora with Nvidia CUDA is expected in 3Q24, with clinical <span style="font-size: var(--content-font-size);">trial starting in 4Q24. </span></li></ul>

Ainos acquired exclusive, permanent licenses for 10 patents and patent applications from its affiliate and development partner, Taiwan Carbon Nano Technology (TCNT), for certain gas sensor and medical device technologies.TCNT is also currently the sole manufacturer of Ainos’ POCTs. The patent coverage includes the US, Germany, China, Japan, and Taiwan.The licensed IP will further enhance the company’s AI Nose and POCT platform, as the lead POCT product Ainos Flora progresses in clinical trial, and design completion for next-gen Ainos Flora with Nvidia CUDA is expected in 3Q24, with clinical trial starting in 4Q24. 

アイノス株式会社 - 主要パートナーからAIノーズ特許のライセンスを取得し、株価はプレミアム価格で評価される